Insider · CIK 0001886794
Harpreet S. Dhaliwal
Files at PCVX (Vaxcyte, Inc.). First filing Jan 2, 2026, latest Jan 2, 2026.
Harpreet S. Dhaliwal files SEC Form 4 as officer at PCVX (Vaxcyte, Inc.). Since Jan 2, 2026, Harpreet S. Dhaliwal has reported 0 open-market buys worth $0 and 1 open-market sell worth $455k, the latest filed on Jan 2, 2026.
A track record needs three past buys with six months of prices behind them; Harpreet S. Dhaliwal has 0, so none is measured yet.
The newest scored trade: sold $455k of PCVX on Dec 31, 2025, filed Jan 2, 2026, scored 50 (moderate). In the last 12 months: 0 buys worth $0 and 1 sell worth $455k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
PCVX: Vaxcyte, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | Vaxcyte, Inc. | $455k 9,743 shares | -29% | +65% from low-50% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 31, 2025 | PCVX VAXCYTE, INC. | 9,743 0.01% of outstanding | $455k | Dec 31, 2025 | none |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | PCVX Vaxcyte, Inc. | FTax withholding Common Stock | -7,651 | $60.36 | $462k | 68,085 | 34 d ago |
| Aug 31, 2026 | PCVX Vaxcyte, Inc. | FTax withholding Common Stock | -361 | $60.74 | $22k | 76,395 | 41 d ago |
| Sep 2, 2026 | PCVX Vaxcyte, Inc. | FTax withholding Common Stock | -659 | $61.58 | $41k | 75,736 | 41 d ago |
| Mar 9, 2026 | PCVX Vaxcyte, Inc. | FTax withholding Common Stock | -604 | $59.32 | $36k | 75,976 | Mar 11, 2026 |
| Feb 26, 2026 | PCVX Vaxcyte, Inc. | AGrant or award Common Stock | +53,409 | $0.00 | $0 | 77,337 | Mar 2, 2026 |
| Feb 28, 2026 | PCVX Vaxcyte, Inc. | FTax withholding Common Stock | -292 | $61.98 | $18k | 77,045 | Mar 2, 2026 |
| Mar 2, 2026 | PCVX Vaxcyte, Inc. | FTax withholding Common Stock | -465 | $61.98 | $29k | 76,580 | Mar 2, 2026 |
| Feb 26, 2026 | PCVX Vaxcyte, Inc. | AGrant or award Stock Option (right to buy)derivative | +46,424 | $0.00 | $0 | 46,424 | Mar 2, 2026 |
| Dec 31, 2025 | PCVX Vaxcyte, Inc. | SOpen-market sale Common Stock | -9,743 | $46.69 | $455k | 23,928 | Jan 2, 2026 |
| Sep 8, 2025 | PCVX Vaxcyte, Inc. | FTax withholding Common Stock | -1,204 | $32.41 | $39k | 33,670 | Sep 10, 2025 |
| Sep 2, 2025 | PCVX Vaxcyte, Inc. | FTax withholding Common Stock | -291 | $31.56 | $9,184 | 36,121 | Sep 4, 2025 |
| Sep 2, 2025 | PCVX Vaxcyte, Inc. | FTax withholding Common Stock | -783 | $31.56 | $25k | 35,338 | Sep 4, 2025 |
| Sep 2, 2025 | PCVX Vaxcyte, Inc. | FTax withholding Common Stock | -464 | $31.56 | $15k | 34,874 | Sep 4, 2025 |
Questions about Harpreet S. Dhaliwal
Answered from the filings on this page, as of the latest one.
Is Harpreet S. Dhaliwal buying or selling?
In the last 12 months Harpreet S. Dhaliwal reported 0 open-market buys worth $0 and 1 open-market sell worth $455k on SEC Form 4; the latest was sold $455k of PCVX on Dec 31, 2025. Grants, option exercises and tax withholding are not counted.
How did Harpreet S. Dhaliwal's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Harpreet S. Dhaliwal has 0.
Where does Harpreet S. Dhaliwal file Form 4?
Harpreet S. Dhaliwal has filed Form 4 at PCVX (Vaxcyte, Inc.) as Chief Technical Ops Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.